【佳學(xué)基因靶向藥物基因檢測】miR-20a 在具有 PKD1 突變的家貓血清中上調(diào)

基因腫瘤檢測公司排名解碼

探索癌癥的早期發(fā)現(xiàn)及檢測看到《PLoS One》在?2022 Dec 20;17(12):e0279337.發(fā)表了一篇題目為《》腫瘤靶向藥物治療基因檢測臨床研究文章。該研究由Marcela Correa Scalon,?Christine Souza Martins,?Gabriel Ginani Ferreira,?Franciele Schlemmer,?Ricardo Titze de Almeida,?Giane Regina Paludo等完成。促進了腫瘤的正確治療與個性化用藥的發(fā)展，進一步強調(diào)了基因信息檢測與分析的重要性。

腫瘤基因檢測及靶向藥物治療研究關(guān)鍵詞：

多囊腎病,PKD,常染色體,顯性遺傳,多囊腎病,ADPKD,腎實質(zhì)囊腫,異質(zhì)性疾病

腫瘤治療檢測基因臨床應(yīng)用結(jié)果

多囊腎病 (PKD)，也稱為常染色體顯性遺傳性多囊腎病 (ADPKD)，是一種以腎實質(zhì)囊腫為特征的遺傳異質(zhì)性疾病。它是家貓賊普遍的遺傳性疾病。微小 RNA（miRNA 或 ncRNA）是短的非編碼單鏈 RNA，可通過影響許多靶基因以及直接調(diào)節(jié) PKD 基因表達來誘導(dǎo) PKD 細胞發(fā)生。我們比較了 9 只 PKD1 突變家貓血漿和血清樣本中 miR-20a、-192、-365、-15b-5p 和 -16-5p 的相對表達譜，通過聚合酶鏈反應(yīng) (PCR) 檢測，以及對照組 (n = 10)。來自具有 PKD1 突變的貓的血液樣本提供了相似濃度的來自血漿或血清的 microRNA。 PKD 組血清 miR-20a 上調(diào)，p < 0.005； Roc 曲線分析顯示 AUC 為 90.1%，臨界值靈敏度為 77.8%，特異性為 100%。該數(shù)據(jù)提供了有關(guān)外周血采樣中腎臟 miRNA 表達的重要信息。

腫瘤發(fā)生與革命國際數(shù)據(jù)庫描述：

Polycystic kidney disease (PKD), also known as autosomal dominant polycystic kidney disease (ADPKD) is a genetically heterogeneous condition characterized by cysts in renal parenchyma. It is the most prevalent inherited disease of domestic cats. MicroRNAs (miRNAs or ncRNA) are short, noncoding, single-stranded RNAs that may induce PKD cytogenesis by affecting numerous targets genes as well as by directly regulating PKD gene expression. We compared the relative expression profile of miR-20a, -192, -365, -15b-5p, and -16-5p from plasma and serum samples of nine domestic cats with PKD1 mutation, detected by polymerase chain reaction (PCR), and a control group (n = 10). Blood samples from cats with PKD1 mutation provide similar concentrations of microRNAs either from plasma or serum. Serum miR-20a is upregulated in PKD group with p < 0.005; Roc curve analysis showed an AUC of 90,1% with a cut-off value sensitivity of 77.8% and specificity of 100%. This data provides important information regarding renal miRNA expression in peripheral blood sampling.